Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study

Masaaki OgasaJohn Guarino


There is an unmet need in the treatment of schizophrenia for effective medications with fewer adverse effects. This study aims to evaluate the efficacy and safety of lurasidone, an atypical antipsychotic, for the treatment of schizophrenia. Patients with an acute exacerbation of schizophrenia were randomized to 6 weeks of double-blind treatment with once-daily, fixed-dose lurasidone 40 mg (N = 50), lurasidone 120 mg (N = 49), or placebo (N = 50). The primary efficacy measure was mean change from baseline to day 42 (last observation carried forward) in the Brief Psychiatric Rating Scale derived (BPRSd) from the Positive and Negative Syndrome Scale (PANSS). Mean change in BPRSd was significantly greater in patients receiving lurasidone 40 and 120 mg/day versus placebo (-9.4 and -11.0 versus -3.8; p = 0.018 and 0.004, respectively). Treatment with lurasidone 120 mg/day was superior to placebo across all secondary measures, including PANSS total (p = 0.009), PANSS positive (p = 0.005), PANSS negative (p = 0.011), and PANSS general psychopathology (p = 0.023) subscales and Clinical Global Impression of Severity (CGI-S; p = 0.001). Treatment with lurasidone 40 mg/day was superior to placebo on the PANSS positive subscale (p = 0.018) ...Continue Reading


May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Feb 1, 1995·Schizophrenia Research·J P LindenmayerR B Hyman
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa
Mar 9, 2004·The Journal of Clinical Psychiatry·American Diabetes AssociationNorth American Association for the Study of Obesity
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 29, 2005·The Journal of Clinical Psychiatry·Eric Q WuJyoti Aggarwal
Dec 7, 2005·Archives of General Psychiatry·Georg KemmlerW Wolfgang Fleischhacker
May 3, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·Michael J Sernyak, Robert A Rosenheck
Dec 31, 2008·Pharmacotherapy·Jolene R BostwickVicki L Ellingrod
Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Sep 3, 2010·Psychiatric Services : a Journal of the American Psychiatric Association·Christoph U CorrellBrian J Cuffel
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel


Dec 25, 2012·CNS Drugs·Mark Sanford
May 15, 2013·Lancet·John R Geddes, David J Miklowitz
Jun 27, 2015·Expert Opinion on Pharmacotherapy·Dawn BruijnzeelRajiv Tandon
Apr 14, 2016·PharmacoEconomics·Krithika RajagopalanAntony Loebel
Oct 5, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·Antony LoebelS R Marder
Mar 27, 2015·Journal of Geriatric Psychiatry and Neurology·Jeffrey CummingsPhilippe H Robert
Jul 8, 2017·Expert Opinion on Investigational Drugs·Lynn McClellanCraig A Erickson
Feb 3, 2016·Therapeutic Advances in Psychopharmacology·Steven G PotkinJohn Guarino
Apr 27, 2018·Journal of Comparative Effectiveness Research·Daisy Ng-MakAntony Loebel
Sep 14, 2017·Expert Opinion on Drug Safety·Maurizio PompiliPaolo Girardi
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Dec 15, 2019·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Teruhiko HiguchiKatsuhiko Hagi
Dec 17, 2019·The American Journal of Psychiatry·Stefan LeuchtJohn M Davis
Apr 26, 2020·Journal of Clinical Psychopharmacology·Herbert Y MeltzerMyung A Lee
Apr 29, 2020·Pharmacotherapy·Constance L ChowAmy M VandenBerg
Jul 22, 2015·International Clinical Psychopharmacology·Jonathan M MeyerAntony Loebel
May 6, 2017·Journal of Child and Adolescent Psychopharmacology·Robert GoldmanRobert L Findling
Mar 4, 2020·CNS & Neurological Disorders Drug Targets·Harika Modugula, Anoop Kumar
May 18, 2020·Schizophrenia Bulletin·Hiroyoshi TakeuchiStefan Leucht
Apr 6, 2019·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Teruhiko HiguchiTakayuki Sato
Sep 6, 2013·Psychopharmacology·Oliver D Howes, Katherine Beck

Related Concepts

Double-Blind Method
Brief Psychiatric Rating Scale
Schizophrenic Psychology
Antipsychotic Effect
Single-Masked Study

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.